Patient in Sarepta Gene Therapy Trial Develops Serious Illness Patient in Sarepta Gene Therapy Trial Develops Serious Illness
Shares of Sarepta Therapeutics Inc plunged 12% after a notice from the U.S. health agency showed a patient in an ongoing study of the company ' s gene therapy for Duchenne muscular dystrophy (DMD) was reported to have developed a serious illness.Reuters Health Information
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news
More News: Brain | Gene Therapy | Genetics | Health | Muscular Dystrophy | Neurology | Neurosurgery | Reflex Sympathetic Dystrophy | Study